+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Activation of PPARgamma increases PTEN expression in pancreatic cancer cells

Biochemical and Biophysical Research Communications 301(1): 50-53

Activation of PPARgamma increases PTEN expression in pancreatic cancer cells

The PI3K pathway contributes to the invasive properties and apoptosis resistance that epitomize pancreatic cancers. PPARgamma is a ligand-activated transcription factor with anti-inflammatory and anti-tumor effects; the mechanisms of tumor suppression are unknown. The purpose of this study was to examine whether activation of PPARgamma can increase the expression of the tumor suppressor PTEN and inhibit PI3K activity. AsPC-1 human pancreatic cancer cells, transfected with a PPRE-luciferase construct, demonstrated increased luminescence following treatment with PPARgamma ligands, indicating the presence of functional PPARgamma protein. The selective PPARgamma ligand rosiglitazone increased PTEN expression in AsPC-1 cells; concurrent treatment with GW9662, which inhibits PPARgamma activation, prevented the increase in PTEN protein levels. Levels of phosphorylated Akt decreased as PTEN levels increased, indicating inhibition of PI3K activity. Taken together, our results suggest that activation of PPARgamma may represent a novel approach for the treatment of pancreatic cancer by increasing PTEN levels and inhibiting PI3K activity.

Accession: 010120055

PMID: 12535639

Related references

Bai, M-Hua.; Ma, H-Bing.; Wang, X-Jing.; Liu, X-Xu.; Xue, X-Huan.; Xue, F-Jie., 2008: Effects of activated PPARgamma on the expression of PTEN gene in pancreatic cancer cells. To explore the relationship between the expression of PTEN gene and the expression of PPARgamma, and the human pancreatic cancer cells PANC-1 were cultured in vitro. The effects of rosiglitazone and GW9662 on the expression of PTEN gene and PTEN p...

Marx, N.; Bourcier, T.; Sukhova, G.K.; Libby, P.; Plutzky, J., 1999: PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. Plasminogen activator inhibitor type-1 (PAI-1) is a major physiological inhibitor of fibrinolysis, with its plasma levels correlating with the risk for myocardial infarction and venous thrombosis. The regulation of PAI-1 transcription by endotheli...

Wang, F.; Jin, R.; Zou, B-Bing.; Li, L.; Cheng, F-Wei.; Luo, X.; Geng, X.; Zhang, S-Quan., 2016: Activation of Toll-like receptor 7 regulates the expression of IFN-λ1, p53, PTEN, VEGF, TIMP-1 and MMP-9 in pancreatic cancer cells. Toll-like receptors (TLRs) are critical in the induction of the immune response in tumor development. TLR7 has previously been demonstrated to be associated with the development of pancreatic cancer, and the release of cytokines and chemokines fro...

Verma, A.; Guha, S.; Wang, H.; Fok, J.Y.; Koul, D.; Abbruzzese, J.; Mehta, K., 2008: Tissue transglutaminase regulates focal adhesion kinase/AKT activation by modulating PTEN expression in pancreatic cancer cells. Pancreatic ductal adenocarcinoma (PDAC) progresses rapidly and exhibits profound resistance to treatment. We recently reported that a great majority of PDAC tumors and tumor cell lines express elevated levels of tissue transglutaminase (TG2). Here...

Teresi, R.E.; Shaiu, C-Wai.; Chen, C-Shih.; Chatterjee, V.Krishna.; Waite, K.A.; Eng, C., 2006: Increased PTEN expression due to transcriptional activation of PPARgamma by Lovastatin and Rosiglitazone. Germline mutations in the tumor suppressor gene PTEN (protein phosphatase and tensin homolog located on chromosome ten) predispose to heritable breast cancer. The transcription factor PPARgamma has also been implicated as a tumor suppressor pertin...

Farrow, B.; O'Connor, K.L.; Hashimoto, K.; Iwamura, T.; Evers, B.Mark., 2003: Selective activation of PPARgamma inhibits pancreatic cancer invasion and decreases expression of tissue plasminogen activator. Background. PPARgamma is a ligand-activated transcription factor with antitumor effects; its ability to inhibit pancreatic cancer invasion is unknown. The purpose of this study was to define the inhibitory effect of PPARgamma ligands on pancreatic...

Chow, J.Y.C.; Ban, M.; Wu, H.L.; Nguyen, F.; Huang, M.; Chung, H.; Dong, H.; Carethers, J.M., 2010: TGF-beta downregulates PTEN via activation of NF-kappaB in pancreatic cancer cells. TGF-beta utilizes receptor-activated SMAD signaling to mediate growth suppression; however, non-SMAD signaling that modulates the TGF-beta response in epithelial cells become apparent when the SMAD signaling is abrogated, a common occurrence in pa...

Toyota, M.; Miyazaki, Y.; Kitamura, S.; Nagasawa, Y.; Hiraoka, S.; Kiyohara, T.; Shinomura, Y.; Matsuzawa, Y., 2000: PPARgamma and RXR synergistically inhibit the expression of cyclin D1 and suppress the growth of pancreatic cancer cells. Gastroenterology 118(4 Suppl 2 Part 2): AGA A1111, April

Anonymous, 2008: TGF-b mediates PTEN suppression and cell motility through calcium-dependent PKC-a activation in pancreatic cancer cells

Rampino, T.; Maggio, M.; Soccio, G.; Gregorini, M.; Guidetti, C.; Marasa, M.; Ranghino, A.; Dal Canton, A., 2002: Activation of PPARgamma downregulates MET protooncogene expression and inhibits growth in renal cancer cells. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 505A, September